Jylamvo (Methotrexate) Patent Expiration, LOE Window & CMS Spending

Jylamvo (Methotrexate) by Shorla: FDA Orange Book LOE 2035-10-28, 9 AB generics, $6K 2024 CMS Part D & Medicaid spend, and $876 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorShorla
FDA Application & PathwayN212479 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-10-28
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$6K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$6K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($876 intro WAC)